Evidence map›Paper›PMID 33372157›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Filling the gaps in the global prevalence map of clinical antimicrobial resistance.

Rik Oldenkamp, Constance Schultsz, Emiliano Mancini, Antonio Cappuccio

Erratum issuedAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. A One Health Comparative Study of MDRAntibiotics (Basel, Switzerland) · 2025
    Article
  5. Turning the Tide Against Carbapenem-resistantOpen forum infectious diseases · 2025
    Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Rik OldenkampAmsterdam Institute for Global Health and Development, 1105 BP Amsterdam, The Netherlands; r.oldenkamp@aighd.org antonio.cappuccio@mssm.edu.ORCID 0000-0002-2245-6987
Constance SchultszAmsterdam Institute for Global Health and Development, 1105 BP Amsterdam, The Netherlands.ORCID 0000-0003-2280-7844
Emiliano ManciniAmsterdam Institute for Global Health and Development, 1105 BP Amsterdam, The Netherlands.ORCID 0000-0002-5613-234X
Antonio CappuccioAmsterdam Institute for Global Health and Development, 1105 BP Amsterdam, The Netherlands; r.oldenkamp@aighd.org antonio.cappuccio@mssm.edu.ORCID 0000-0002-8266-2344

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surveillance is critical in containing globally increasing antimicrobial resistance (AMR). Affordable methodologies to prioritize AMR surveillance efforts are urgently needed, especially in low- and middle-income countries (LMICs), where resources are limited. While socioeconomic characteristics correlate with clinical AMR prevalence, this correlation has not yet been used to estimate AMR prevalence in countries lacking surveillance. We captured the statistical relationship between AMR prevalence and socioeconomic characteristics in a suite of beta-binomial principal component regression models for nine pathogens resistant to 19 (classes of) antibiotics. Prevalence data from ResistanceMap were combined with socioeconomic profiles constructed from 5,595 World Bank indicators. Cross-validated models were used to estimate clinical AMR prevalence and temporal trends for countries lacking data. Our approach provides robust estimates of clinical AMR prevalence in LMICs for most priority pathogens (cross-validated

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsAnti-Infective AgentsBacterial InfectionsCarbapenemsDrug Resistance, BacterialDrug Resistance, MicrobialDrug Resistance, Multiple, BacterialEpidemiological MonitoringEscherichia coliHumansKlebsiella pneumoniaePrevalenceAnti-Bacterial AgentsAnti-Infective AgentsCarbapenemsantimicrobial resistancecarbapenem-resistant Acinetobacter baumanniiglobal healthsurveillancethird-generation cephalosporin-resistant Escherichia coli

Identifiers

PMID33372157
PMCPMC7817194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.